Viral Vector & Plasmid DNA Manufacturing Market: Plasmid DNA segment accounted for major market share

Transparency Market Research (TMR) has published a new report titled, ‘Viral Vector & Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027.’ According to the report, the global viral vector & plasmid DNA manufacturing market was valued at US$ 0.4 Bn in 2018 and is projected to expand at a CAGR of 23.3% from 2019 to 2027.

Overview

  • Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy.
  • There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors. Plasmid DNA is also employed as a vector in gene therapy and vaccinology. Plasmid DNA is used as raw material in the production of various viral vectors.
  • Technological advancements, increase in awareness about viral vector-based treatments, and rise in demand for vector-based products for research are the major factors anticipated to drive the global viral vector & plasmid DNA manufacturing market during the forecast period
  • North America held major share of the global viral vector & plasmid DNA manufacturing market in 2018. Availability of the U.S. FDA (Food and Drug Administration) approved gene therapy products and rich product pipeline are the factors expected to augment the viral vector & plasmid DNA manufacturing market in the region during the forecast period.
  • The viral vector & plasmid DNA manufacturing market in Asia Pacific is likely to expand at a high CAGR of 24.5% from 2019 to 2027, due to recent developments in regenerative medicines, rise in prevalence of chronic diseases, and increase in demand for gene therapies. Additionally, demand for viral vector & plasmid DNA is increasing in emerging markets such as India and China.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30428

Rise in Prevalence of Cancer, Genetic Diseases, and Infectious Diseases to Propel Global Viral Vector & Plasmid DNA Manufacturing Market

  • Rise in prevalence of cancer and genetic diseases is projected to augment the global viral vector & plasmid DNA manufacturing market during the forecast period
  • According to the Cancer Research UK, 17 million new cases of cancer were reported globally in 2018 and the four most common types of cancer were breast, lung, bowel, and prostate, which account for around 43% of all new cases
  • According to the National Cancer Institute, cancer is among the leading causes of death across the world, and the number of new cases per year is anticipated to rise to 23.6 million by 2030.

Request for Analysis of COVID-19 Impact on

Plasmid DNA Segment Dominated Global Viral Vector & Plasmid DNA Manufacturing Market

  • In terms of type, the global viral vector & plasmid DNA manufacturing market can be classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others
  • The plasmid DNA segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is expected to continue during the forecast period
  • Increase in use of plasmid DNA as raw material in the manufacture of viral vectors is likely to drive the segment during the forecast period

Request for Analysis of COVID-19 Impact on Viral Vector & Plasmid DNA Manufacturing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30428

Cancer to be Promising Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

  • Based on disease, the global viral vector & plasmid DNA manufacturing market has been categorized into genetic disorders, cancer, infectious diseases, and others
  • The cancer segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is projected to continue during the forecast period owing to large number of ongoing clinical trials and availability of approved viral vector-based cancer drugs

Biotech Companies to be Lucrative Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

  • In terms of end-user, the global viral vector & plasmid DNA manufacturing market has been categorized into biotech companies and research institutes
  • The biotech companies segment held major share of the global viral vector & plasmid DNA manufacturing market in 2018
  • Increase in number of viral vector-based cancer drugs being manufactured by multinational players and several clinical trials underway for the treatment of various cancers are anticipated to propel the segment during the forecast period

North America to Dominate Global Market; Asia Pacific to Offer Significant Incremental Opportunity

  • In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
  • North America is projected to account for major share of the global viral vector & plasmid DNA manufacturing market during the forecast period, owing to high acceptance of viral vector-based gene therapies for the treatment of rare diseases and availability of FDA-approved gene therapies
  • The viral vector & plasmid DNA manufacturing market in Asia Pacific is anticipated to grow at a rapid pace in the next few years. Several ongoing gene therapy clinical trials in countries in China and Japan and high incidence of cancer are likely to fuel the growth of the market in the emerging countries of Asia Pacific.

Buy Viral Vector & Plasmid DNA Manufacturing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=30428&ltype=S

Key Players in Global Viral Vector & Plasmid DNA Manufacturing Market

  • Key players operating in the global viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies, Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza.

Browse More Trending Reports by Transparency Market Research:

Drug and Alcohol Rehabilitation Market: https://www.transparencymarketresearch.com/drug-alcohol-rehabilitation-market.html

Central Nervous System Stimulant Drugs Market: https://www.transparencymarketresearch.com/central-nervous-system-stimulant-drugs-market.html

Cachexia Treatment Market: https://www.transparencymarketresearch.com/cachexia-treatment-market.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news